Angiogenesis
-
Hemostemix Expands Phase 1 Trial to Include Refractory Angina
Hemostemix (HMTXF) has completed its Phase 1 trial protocol for refractory angina using ACP-01. This open-label study will enroll 20-100 adults with severe angina to assess the feasibility and safety of intracoronary ACP-01 delivery in an outpatient setting. Secondary endpoints include monitoring chest pain, six-minute walk distance, quality of life, and LVEF. The trial will also explore the effects of single versus double treatments and analyze BNP levels to predict treatment response.
